ArticlePharmaceuticals (Basel, Switzerland)2025

Evaluation of the Potential Benefits of Trimetazidine in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Controlled Trial.

Maha Youssif et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.